Aspen Neuroscience, Inc. filed a Form 8-K on November 2, 2026, disclosing the closing of its initial public offering, the pricing and share count of that offering, and the concurrent effectiveness of its amended and restated certificate of incorporation and bylaws.

Key Highlights

  • IPO completed: Aspen Neuroscience completed its initial public offering on November 2, 2026, according to the filing.
  • Shares sold: The company sold 9,375,000 shares of common stock, par value $0.0001 per share, in the offering.
  • Offering price: Shares were priced to the public at $15.00 per share.
  • Gross proceeds: The company reported gross proceeds of approximately $140.6 million, before deducting underwriting discounts, commissions, and offering expenses.
  • Governing documents effective: The amended and restated certificate of incorporation and amended and restated bylaws became effective on November 2, 2026, in connection with the IPO closing.
  • Emerging growth company: The registrant indicated it qualifies as an emerging growth company as defined under applicable securities regulations.

Aspen Neuroscience IPO Closing: Offering Terms and Governance Changes

According to the filing, Aspen Neuroscience, Inc. (NASDAQ:ASPE) completed its initial public offering on November 2, 2026. The company disclosed that 9,375,000 shares of common stock, par value $0.0001 per share, were sold at a public offering price of $15.00 per share, generating gross proceeds of approximately $140.6 million before deducting underwriting discounts and commissions and offering expenses payable by the company.

The filing also reported that, in connection with the IPO closing, the company's amended and restated certificate of incorporation and amended and restated bylaws became effective on November 2, 2026. The filing stated that the company's board of directors and stockholders had previously approved both documents to take effect immediately prior to the IPO closing. The filing directs readers to the section titled "Description of Capital Stock" in the final prospectus filed with the SEC on October 30, 2026, pursuant to Rule 424(b), which relates to the Registration Statement on Form S-1 filed on October 9, 2026 (File No. 333-299393), for a fuller description of the certificate and bylaws.

The filing noted that the descriptions of the certificate and bylaws are "qualified in their entirety by reference to the full text of the Certificate and Bylaws," which were attached as Exhibit 3.1 and Exhibit 3.2, respectively. The 8-K was signed by Jeffrey Boerneke, General Counsel and Secretary of Aspen Neuroscience, Inc.

What Was Disclosed

Aspen Neuroscience disclosed the closing of its IPO, the sale of 9,375,000 shares at $15.00 per share for approximately $140.6 million in gross proceeds, and the effectiveness of its amended and restated certificate of incorporation and bylaws, all as of November 2, 2026.